RESEARCH ARTICLE


Visual Acuity, Contrast Sensitivity and Color Vision Three Years After Iodine-125 Brachytherapy for Choroidal and Ciliary Body Melanoma



Irena Tsui 1, Robert M Beardsley 1, Tara A McCannel 1, Scott C Oliver 2, Melissa W Chun 1, Steve P Lee 3, Phillip E Chow 3, Nzhde Agazaryan 3, Fei Yu 1, Bradley R Straatsma*, 1
1 Department of Ophthalmology and Jules Stein Eye Institute, University of California, Los Angeles, Los Angeles, CA, USA
2 Department of Ophthalmology, University of Colorado, Denver, Aurora, CO, USA
3 Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, USA

Article Information


Identifiers and Pagination:

Year: 2015
Volume: 9
First Page: 131
Last Page: 135
Publisher ID: TOOPHTJ-9-131
DOI: 10.2174/1874364101509010131

Article History:

Received Date: 13/2/2015
Revision Received Date: 29/4/2015
Acceptance Date: 11/5/2015
Electronic publication date: 26/6/2015
Collection year: 2015

Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 3081
Abstract HTML Views: 2181
PDF Downloads: 631
Total Views/Downloads: 5893
Unique Statistics:

Full-Text HTML Views: 1581
Abstract HTML Views: 1193
PDF Downloads: 412
Total Views/Downloads: 3186



Creative Commons License
© Tsui et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Jules Stein Eye Institute,100 Stein Plaza, UCLA, Los Angeles, CA 90095-7000, USA; Tel: (310) 825-5051; Fax: (310) 206-4293; E-mail: straatsma@jsei.ucla.edu


Abstract

Purpose :

To report visual acuity, contrast sensitivity and color vision prior to, 1 year after, 2 years after and 3 years after iodine-125 brachytherapy for choroidal and ciliary body melanoma (CCM).

Design :

Prospective interventional case series.

Participants :

Thirty-seven patients (37 eyes) with CCM.

Methods :

Patients had best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity, Pelli-Robson contrast sensitivity and Hardy-Rand-Rittler color vision measurement; comprehensive ophthalmology examination; optical coherence tomography; and ultrasonography at baseline prior to, 1 year after, 2 years after and 3 years after I-125 brachytherapy.

Main Outcome Measures :

Visual acuity, contrast sensitivity and color vision prior to, 1 year after, 2 years after and 3 years after brachytherapy.

Results :

Nineteen (19) men and 18 women with mean age of 58 years (SD 13, range 30-78) prior to, 1 year after, 2 years after and 3 years after brachytherapy had mean best-corrected visual acuity of 77 letters (20/32), 65 letters (20/50), 56 letters (20/80) and 47 letters (20/125); contrast sensitivity of 30, 26, 22 and 19 letters; color vision of 26, 20, 17 and 14 test figures, respectively. Decrease in visual acuity, contrast sensitivity and color vision was statistically significant from baseline at 1 year, 2 years, and 3 years after brachytherapy. Decreased acuity at 3 years was associated with mid-choroid and macula melanoma location, ≥ 4.1 mm melanoma height, radiation maculopathy and radiation optic neuropathy.

Conclusion :

1, 2 and 3 years after brachytherapy, eyes with CCM had significantly decreased visual acuity, contrast sensitivity and color vision.

Keywords: Brachytherapy, choroidal melanoma, ciliary body melanoma, contrast sensitivity, visual acuity.